Related references
Note: Only part of the references are listed.Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction Rationale and Design of GALACTIC-HF
John R. Teerlink et al.
JACC-HEART FAILURE (2020)
Cardiac Calcitropes, Myotropes, and Mitotropes JACC Review Topic of the Week
Mitchell A. Psotka et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY
Simon D. Harding et al.
NUCLEIC ACIDS RESEARCH (2018)
Effects of the cardiac myosin activator Omecamtiv-mecarbil on severe chronic aortic regurgitation in Wistar rats
Bachar El-Oumeiri et al.
BMC CARDIOVASCULAR DISORDERS (2018)
Experimental design and analysis and their reporting II: updated and simplified guidance for authors and peer reviewers
Michael J. Curtis et al.
BRITISH JOURNAL OF PHARMACOLOGY (2018)
Dilated cardiomyopathy myosin mutants have reduced force-generating capacity
Zoltan Ujfalusi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2018)
Highly variable contractile performance correlates with myocyte content in trabeculae from failing human hearts
Michelle L. Munro et al.
SCIENTIFIC REPORTS (2018)
Normalization of force to muscle cross-sectional area: A helpful attempt to reduce data scattering in contractility studies?
Simon Pecha et al.
ACTA PHYSIOLOGICA (2018)
Opposite diastolic effects of omecamtiv mecarbil versus dobutamine and ivabradine co-treatment in pigs with acute ischemic heart failure
Leif Ronning et al.
PHYSIOLOGICAL REPORTS (2018)
Omecamtiv Mecarbil Enhances the Duty Ratio of Human -Cardiac Myosin Resulting in Increased Calcium Sensitivity and Slowed Force Development in Cardiac Muscle
Anja M. Swenson et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2017)
Frequency-dependent effects of omecamtiv mecarbil on cell shortening of isolated canine ventricular cardiomyocytes
Balazs Horvath et al.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2017)
Mechanistic and structural basis for activation of cardiac myosin force production by omecamtiv mecarbil
Vicente J. Planelles-Herrero et al.
NATURE COMMUNICATIONS (2017)
Dose-Dependent Effects of the Myosin Activator Omecamtiv Mecarbil on Cross-Bridge Behavior and Force Generation in Failing Human Myocardium
Ranganath Mamidi et al.
CIRCULATION-HEART FAILURE (2017)
Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure The ATOMIC-AHF Study
John R. Teerlink et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2016)
Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial
John R. Teerlink et al.
LANCET (2016)
Omecamtiv Mecarbil Modulates the Kinetic and Motile Properties of Porcine beta-Cardiac Myosin
Yingying Liu et al.
BIOCHEMISTRY (2015)
The novel cardiac myosin activator omecamtiv mecarbil increases the calcium sensitivity of force production in isolated cardiomyocytes and skeletal muscle fibres of the rat
L. Nagy et al.
BRITISH JOURNAL OF PHARMACOLOGY (2015)
Molecular effects of the myosin activator omecamtiv mecarbil on contractile properties of skinned myocardium lacking cardiac myosin binding protein-C
Ranganath Mamidi et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2015)
Structural basis for drug-induced allosteric changes to human β-cardiac myosin motor activity
Donald A. Winkelmann et al.
NATURE COMMUNICATIONS (2015)
Divergent effects of α- and β-myosin heavy chain isoforms on the N terminus of rat cardiac troponin T
Ranganath Mamidi et al.
JOURNAL OF GENERAL PHYSIOLOGY (2013)
Cardiac inotropes: current agents and future directions
Gerd Hasenfuss et al.
EUROPEAN HEART JOURNAL (2011)
The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial
John G. F. Cleland et al.
LANCET (2011)
Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study
John R. Teerlink et al.
LANCET (2011)
Cardiac Myosin Activation: A Potential Therapeutic Approach for Systolic Heart Failure
Fady I. Malik et al.
SCIENCE (2011)
Improvement of Cardiac Function by a Cardiac Myosin Activator in Conscious Dogs With Systolic Heart Failure
You-Tang Shen et al.
CIRCULATION-HEART FAILURE (2010)
Early afterdepolarizations and cardiac arrhythmias
James N. Weiss et al.
HEART RHYTHM (2010)
Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography
Sherif F. Nagueh et al.
EUROPEAN JOURNAL OF ECHOCARDIOGRAPHY (2009)
Human heart β-adrenoceptors:: β1-adrenoceptor diversification through 'affinity states' and polymorphism
P. Molenaar et al.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2007)
Increasing ryanodine receptor open probability alone does not produce arrhythmogenic calcium waves - Threshold sarcoplasmic reticulum calcium content is required
Luigi A. Venetucci et al.
CIRCULATION RESEARCH (2007)
Mechanisms and use of calcium-sensitizing agents in the failing heart
DA Kass et al.
CIRCULATION (2006)
Carvedilol blocks beta(2)- more than beta(1)-adrenoceptors in human heart
P Molenaar et al.
CARDIOVASCULAR RESEARCH (2006)
Role of phospholamban phosphorylation on Thr17 in cardiac physiological and pathological conditions
A Mattiazzi et al.
CARDIOVASCULAR RESEARCH (2005)
(-)-CGP 12177 increases contractile force and hastens relaxation of human myocardial preparations through a propranolol-resistant state of the beta(1)-adrenoceptor
D Sarsero et al.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2003)
Both β2- and β1-adrenergic receptors mediate hastened relaxation and phosphorylation of phospholamban and troponin I in ventricular myocardium of fallot infants, consistent with selective coupling of β2-adrenergic receptors to Gs-protein
P Molenaar et al.
CIRCULATION (2000)
Share Paper
